title: Terrapinn's world influenza congress Europe 2009. Part 2.
abstract: Terrapinn's World Influenza Congress Europe 2009, held in Brussels, included topics covering new developments in the field of influenza vaccination. This conference report highlights selected presentations on the use of novel technologies for developing vaccines for influenza. Investigational vaccines discussed include Multimeric-001 (BiondVax Pharmaceuticals Ltd), NB-1008 (NanoBio Corp) and an influenza vaccine containing the CAF-01 adjuvant (Statens Serum Institut).
authors.affiliation: Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK. claire.veryard@thomsonreuters.com
authors.forename: Claire
authors.initials: C
authors.lastname: Veryard
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D015195:Drug Design; D015507:Drugs, Investigational / Q000494:pharmacology; D006801:Humans; D007252:Influenza Vaccines / Q000276:immunology*; D007251:Influenza, Human / Q000517:prevention & control*; D013678:Technology, Pharmaceutical / Q000379:methods
chemical_list: D015507:Drugs, Investigational; D007252:Influenza Vaccines